Univariate logistic regression indicated that the upregulation of APOL6 was associated with improved response rates in melanoma, urothelial cancer and breast cancer (the ORs (95%CI) were 9.35 (2.63, 33.26), 2.96 (1.65, 5.31) and 4.44 (1.61, 12.27), respectively, as shown in Figure 2A, Table 1 and Table S1). This evidence concerns the gene APOL6 and melanoma.